Table 1 The Demographic and Clinical Features of 109 SOF-naïve Patients Subjected to Analysis for the NS5B Region of HCV.

Age (years old)^†

67 (27–87)

67 (41–87)

67 (27–85)

0.749^a

Men / Women^††

39 (35.8) / 70 (64.2)

21 (42.0) / 29 (58.0)

18 (30.5) / 41 (69.5))

0.234^b

Naïve

69 (63.3)

28 (56.0)

41 (69.5)

0.101

IFN or Peg-IFN monotherapy

6 (5.5)

2 (4.0)

4 (6.8)

Peg-IFN + RBV 

21 (19.3)

14 (28.0)

7 (11.9)

TVR/SMV/VAN + Peg-IFN +RBV

11 (10.1)

6 (12.0)

5 (8.5)

DCV + ASV

2 (1.8)

0 (0)

2 (3.4)

SOF/LDV

0 (0)

0 (0)

0 (0)

Previous IFN/Peg-IFN^††

38 (34.9)

22 (44.0)

16 (27.1)

0.073^b

Previous RBV^††

32 (29.4)

20 (40.0)

12 (20.3)

0.034^b

Previous NS3/4A-PI^††

13 (11.9)

6 (12.0)

7 (11.9)

1.000^b

Previous NS5A-I^††

2 (1.8)

0 (0)

2 (3.4)

0.499^b

Previous therapies for HCC^††

11 (10.2%)

3 (6.0)

8 (13.6)

0.221^b

Hemoglobin (g/dL)^†

13.9 (9.0–17.7)

13.9 (9.4–17.2)

13.7 (9.0–17.7)

0.874^a

Platelets (10³/mm³)^†

156 (46–374)

146 (46–374)

165 (53–350)

0.196^a

Albumin (g/dL)^†

4.1 (2.9–4.8)

4.1 (3.4–4.7)

4.1 (2.9–4.8)

0.270^a

AST (U/L)^†

40 (15–135)

40 (15–135)

36 (18–127)

0.440^a

ALT (U/L)^†

36 (10–167)

36 (10–167)

63 (34–119)

0.465^a

α-fetoprotein (ng/mL)^†

4.5 (2.0–57.1)

4.6 (2.0–57.1)

4.0 (2.0–21.6)

0.297^a

HCV-RNA (Log IU/mL)^†

6.2 (4.0–7.1)

6.1 (4.0–7.1)

6.4 (4.1–7.1)

0.208^a

FIB4 index^†

2.97 (0.36–17.25)

3.05 (0.82–14.71)

2.80 (0.36–17.25)

0.444^a

<3.25^††

60 (55.0)

27 (54.0)

33 (55.9)

0.849^b

≥3.25^††

49 (45.0)

23 (46.0)

26 (44.1)